Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging - MarketWatch
1. Eli Lilly's stock fell 14.7%, marking its worst drop in 26 years. 2. Weight-loss trial results for orforglipron didn’t meet market expectations. 3. Zepbound sales rose 172% but failed to offset negative trial results. 4. Competitor Novo Nordisk's drug showed better efficacy in weight loss. 5. Lilly raised 2025 EPS guidance despite significant stock downturn.